BioCentury's weekly flagship publication provides analysis, interpretation and commentary on biopharma industry corporate performance, product discovery and development, emerging companies and technologies, regulatory events and innovation, public policy and financial markets.
› See a sample Cover Story
› See a sample Company Deal Story
› See a sample Product Discovery & Development Story
› See a sample Ebb & Flow Financial Story
› See a sample Emerging Company Profile
› See a sample Regulatory Story
› See a sample Public Policy Story
A subscription to BioCentury includes, at no additional cost, these essential value-added components:
BioCentury Week in Review
Provides a weekly compendium of biopharma deals, clinical and regulatory events, and financial transactions.
› See the BioCentury Week in Review
Published every business day to be viewed on mobile devices or online, providing busy executives and investors with a concise report of key industry news events that are selected for importance by BioCentury's experienced editors.
› See the Daily Extra
BioCentury Quarterly Stock Roundup
Tracking more than 500 public biotech companies in the U.S., Europe, Canada and Asia-Pacific, this complete overview records the performance of 44 industry subgroups, the BioCentury 100 Index and other benchmark indices, and each quarter's fundraising activity.
Your subscription includes these special BioCentury editions every year:
|› The "Buyside View" every January
› The "Iceberg Annual Report on European Biotech" every May
› The "Back to School Issue" every September
› The "Quarterly Stock Review" issued at the end of each quarter